Literature DB >> 11575441

Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus.

R C Fitzgerald1, I T Saeed, D Khoo, M J Farthing, W R Burnham.   

Abstract

Esophageal adenocarcinoma is increasing in incidence and has a high mortality unless detected early. Barrett's esophagus is the only known risk factor for this cancer; however, whether endoscopic surveillance reduces morbidity and mortality is controversial. Endoscopic cancer surveillance programes for Barrett's esophagus are not routinely practiced in the UK, and this is the first study to examine whether a rigorous surveillance protocol increases the detection rate of early oesophageal cancer. All patients with a diagnosis of Barrett's esophagus or associated adenocarcinoma attending Havering Hospitals NHS Trust between 1992 and 1998 were included. A retrospective analysis was made of patients undergoing informal surveillance (96 patients, 1992-1997) and a prospective analysis was conducted following the implementation of a rigorous protocol (108 patients, 1997-1998). Over the same time periods Barrett's associated cancers diagnosed in patients not undergoing surveillance were analyzed (262 patients 1992-1997, 98 patients 1997-1998). From 1992 to 1997, one case of high-grade dysplasia was detected (N = 96, 1%). From 1997 to 1998, two cancers and three high-grade dysplasias were detected during rigorous surveillance (N = 108, 4.6%). Three of these patients have had curative esophagectomies (one high-grade dysplasia and two T1,N0,M0 tumors). In 1992-1997, 10 patients were found to have cancer in previously undiagnosed Barrett's esophagus (N = 262, 3.8%). Of 3/10 cancers treated surgically, one patient had a curative procedure (T1,N0,M0). In 1997-1998, nine patients were found to have de novo Barrett's esophagus cancer (N = 88, 10.2%) and three had curative resections (T1,N0,M0). Two of the patients with T1 lesions had no endoscopic evidence of cancer but were detected as a result of the multiple biopsy protocol. In conclusion, a rigorous biopsy protocol increases the detection of early cancer in Barrett's esophagus.

Entities:  

Mesh:

Year:  2001        PMID: 11575441     DOI: 10.1023/a:1010678913481

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium.

Authors:  A J Cameron; C T Lomboy
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

2.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

Review 3.  The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett.

Authors:  S J Spechler; R K Goyal
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

4.  Continuing climb in rates of esophageal adenocarcinoma: an update.

Authors:  W J Blot; S S Devesa; J F Fraumeni
Journal:  JAMA       Date:  1993-09-15       Impact factor: 56.272

5.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

6.  Cost effectiveness of detecting Barrett's cancer.

Authors:  T A Wright; M R Gray; A I Morris; I T Gilmore; A Ellis; H L Smart; M Myskow; J Nash; R J Donnelly; A N Kingsnorth
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

7.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

8.  Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease.

Authors:  C Winters; T J Spurling; S J Chobanian; D J Curtis; R L Esposito; J F Hacker; D A Johnson; D F Cruess; J D Cotelingam; M S Gurney
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

9.  Is Barrett's metaplasia the source of adenocarcinomas of the cardia?

Authors:  G W Clark; T C Smyrk; P Burdiles; S F Hoeft; J H Peters; M Kiyabu; R A Hinder; C G Bremner; T R DeMeester
Journal:  Arch Surg       Date:  1994-06

10.  Risk stratification and long-term results after surgical treatment of carcinomas of the thoracic esophagus and cardia. A 25-year retrospective study.

Authors:  O Lund; H H Kimose; M T Aagaard; J M Hasenkam; M Erlandsen
Journal:  J Thorac Cardiovasc Surg       Date:  1990-02       Impact factor: 5.209

View more
  28 in total

1.  Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study.

Authors:  Mauro Rossi; Marco Barreca; Nicola de Bortoli; Cristina Renzi; Stefano Santi; Alessandro Gennai; Massimo Bellini; Francesco Costa; Massimo Conio; Santino Marchi
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

Review 2.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 3.  Barrett's esophagus: diagnosis and management.

Authors:  Swathi Eluri; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2017-01-18       Impact factor: 9.427

Review 4.  Acetic acid chromoendoscopy: Improving neoplasia detection in Barrett's esophagus.

Authors:  Fergus J Q Chedgy; Sharmila Subramaniam; Kesavan Kandiah; Sreedhari Thayalasekaran; Pradeep Bhandari
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

5.  Guidance on the effective use of upper gastrointestinal histopathology.

Authors:  Maurice B Loughrey; Brian T Johnston
Journal:  Frontline Gastroenterol       Date:  2014-01-17

Review 6.  Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?

Authors:  Fouad Otaki; Prasad G Iyer
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

7.  Evolving changes in the management of early oesophageal adenocarcinoma in a tertiary centre.

Authors:  N J O'Farrell; J V Reynolds; N Ravi; J O Larkin; V Malik; G F Wilson; C Muldoon; D O'Toole
Journal:  Ir J Med Sci       Date:  2012-12-16       Impact factor: 1.568

Review 8.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

9.  The patterns of reflux can affect regression of non-dysplastic and low-grade dysplastic Barrett's esophagus after medical and surgical treatment: a prospective case-control study.

Authors:  Salvatore Tolone; Paolo Limongelli; Marco Romano; Alessandro Federico; Giovanni Docimo; Roberto Ruggiero; Luigi Brusciano; Gianmattia Del Genio; Ludovico Docimo
Journal:  Surg Endosc       Date:  2014-07-17       Impact factor: 4.584

10.  Transoral endoscopic inner layer esophagectomy: management of high-grade dysplasia and superficial cancer with organ preservation.

Authors:  Bart P L Witteman; Tyler J Foxwell; Sandy Monsheimer; Andres Gelrud; George M Eid; Alejandro Nieponice; Robert W O'Rourke; Toshitaka Hoppo; Nicole D Bouvy; Stephen F Badylak; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2009-10-14       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.